Stockscreener 앱 받기
22.41
1.93%
-0.44
전일 마감가:
$22.85
열려 있는:
$22.86
하루 거래량:
1.95M
Relative Volume:
0.98
시가총액:
$2.47B
수익:
$12.59M
순이익/손실:
$-212.39M
주가수익비율:
-7.2635
EPS:
-3.0853
순현금흐름:
$-185.92M
1주 성능:
+6.36%
1개월 성능:
-4.56%
6개월 성능:
+131.75%
1년 성능:
+127.28%
1일 변동 폭
$22.24
$23.35
1주일 범위
$19.60
$23.35
52주 변동 폭
$5.1501
$25.30
이뮤놈 Stock (IMNM) Company Profile
명칭
Immunome Inc
전화
610-321-3700
주소
18702 N. CREEK PARKWAY, BOTHELL
IMNM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
22.41 | 2.52B | 12.59M | -212.39M | -185.92M | -3.0853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
이뮤놈 Stock (IMNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-01 | 개시 | Truist | Buy |
| 2025-09-22 | 개시 | Goldman | Buy |
| 2025-09-05 | 개시 | Craig Hallum | Buy |
| 2025-04-02 | 개시 | Lake Street | Buy |
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-04-30 | 개시 | JP Morgan | Overweight |
| 2024-04-15 | 개시 | Guggenheim | Buy |
| 2024-01-29 | 개시 | Leerink Partners | Outperform |
| 2023-12-19 | 개시 | Wedbush | Outperform |
| 2021-10-29 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
이뮤놈 주식(IMNM)의 최신 뉴스
Immunome (IMNM) Is Up 6.4% After Strong Phase 3 Varegacestat Data and 2026 FDA PlanWhat's Changed - simplywall.st
Bond Watch: Does Immunome Inc have declining or rising EPSEarnings Growth Report & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat SuccessHas The Bull Case Changed? - Yahoo Finance
Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals - Yahoo Finance
Immunome, Inc. $IMNM Holdings Boosted by Nisa Investment Advisors LLC - MarketBeat
Is Immunome Inc affected by consumer sentiment2025 Retail Activity & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Wedbush Reiterates Outperform Rating for IMNM with $31 Price Tar - GuruFocus
Immunome (NASDAQ:IMNM) Trading 8.1% HigherHere's Why - MarketBeat
Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? - Insider Monkey
Immunome (NASDAQ:IMNM) Receives Outperform Rating from Wedbush - MarketBeat
Assessing Immunome (IMNM) Valuation After Phase 3 Success And Upcoming J.P. Morgan Conference Presentation - Sahm
Returns Recap: Does Immunome Inc have declining or rising EPSWeekly Trade Summary & Long-Term Safe Investment Ideas - baoquankhu1.vn
Responsive Playbooks and the IMNM Inflection - Stock Traders Daily
Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms - TechStock²
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Jim Cramer on Immunome: “If You Want to Speculate on It, Fine” - Insider Monkey
Is Immunome Inc. stock supported by strong fundamentalsMarket Rumors and News & Affordable Market Investment - Улправда
Jim Cramer on Immunome: "If You Want to Speculate on It, Fine" - Finviz
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Franklin Credit Management CorporationImmunome to Present at 44th Annual J.P. Morgan Healthcare Conference - FinancialContent
Immunome (IMNM) stock drops 5% as biotech slips; investors look to Jan. 14 update - TechStock²
Immunome’s Stock Under the Microscope: Can IMNM Turn Recent Volatility Into a Breakout? - AD HOC NEWS
Immunome (NASDAQ:IMNM) Shares Down 7%Time to Sell? - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Decliners Report: Can Immunome Inc stock deliver strong Q4 earningsJuly 2025 Outlook & Weekly High Return Opportunities - Bộ Nội Vụ
Immunome’s Phase 1 Cancer Study: A Potential Game-Changer? - MSN
Understanding the Setup: (IMNM) and Scalable Risk - Stock Traders Daily
Immunome (IMNM) CEO Siegall buys $100k in shares By Investing.com - Investing.com South Africa
Top Executive Makes Bold Move With Fresh Immunome Stock Purchase - TipRanks
Insider Buying: Clay Siegall Acquires Additional Shares of Immun - GuruFocus
Immunome (NASDAQ:IMNM) CEO Purchases $100,018.35 in Stock - MarketBeat
Immunome (IMNM) CEO Siegall buys $100k in shares - Investing.com
Top Biotech Stocks To ConsiderDecember 15th - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Immunome (IMNM) - The Globe and Mail
Former CEO Of Seagen Buys Shares Of Immunome – Insider Weekends (NASDAQ:IMNM) - Seeking Alpha
Why Immunome stock surged today - MSN
Immunome (IMNM): Assessing Valuation After Strong Phase 3 Varegacestat Data and $400 Million Equity Raise - Sahm
Immunome (IMNM) price target increased by 33.44% to 34.94 - MSN
Immunome, a top 3% stock, just delivered a 'knockout' to Merck KGaA - MSN
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 383,200 Shares - MarketBeat
Guggenheim reiterates Buy rating on Immunome stock following $400M financing By Investing.com - Investing.com South Africa
Guggenheim reiterates Buy rating on Immunome stock following $400M financing - Investing.com Nigeria
Hedge Fund and Insider Trading News: Michael Hintze, Xavier Majic, Stanley Druckenmiller, Warren Buffett, Bill Ackman, Bridgewater Associates, Citadel Investment Group, Infini Capital, Immunome Inc (IMNM), White Mountains Insurance Group Ltd (WTM), a - Insider Monkey
Siegall buys Immunome (IMNM) shares worth $149k By Investing.com - Investing.com Nigeria
Immunome (NASDAQ:IMNM) Insider Purchases $204,900.00 in Stock - MarketBeat
이뮤놈 (IMNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
이뮤놈 주식 (IMNM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Barchas Isaac | Director |
Dec 22 '25 |
Sale |
21.74 |
383,200 |
8,330,080 |
2,031,181 |
| SIEGALL CLAY B | President and CEO |
Dec 19 '25 |
Buy |
20.48 |
7,278 |
149,053 |
860,525 |
| Tsai Philip | Chief Technical Officer |
Dec 19 '25 |
Buy |
20.49 |
10,000 |
204,900 |
43,300 |
| SIEGALL CLAY B | President and CEO |
Dec 18 '25 |
Buy |
21.50 |
46,511 |
999,986 |
853,247 |
| Higgins Jack | Chief Scientific Officer |
Sep 10 '25 |
Option Exercise |
1.35 |
22,000 |
29,700 |
40,729 |
| BIENAIME JEAN JACQUES | Director |
Jun 03 '25 |
Buy |
9.38 |
5,000 |
46,900 |
36,415 |
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
4.73%
0.92%
자본화:
|
볼륨(24시간):